JP2024522718A5 - - Google Patents

Info

Publication number
JP2024522718A5
JP2024522718A5 JP2023577349A JP2023577349A JP2024522718A5 JP 2024522718 A5 JP2024522718 A5 JP 2024522718A5 JP 2023577349 A JP2023577349 A JP 2023577349A JP 2023577349 A JP2023577349 A JP 2023577349A JP 2024522718 A5 JP2024522718 A5 JP 2024522718A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
alkyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522718A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/033523 external-priority patent/WO2022266162A1/en
Publication of JP2024522718A publication Critical patent/JP2024522718A/ja
Publication of JP2024522718A5 publication Critical patent/JP2024522718A5/ja
Pending legal-status Critical Current

Links

JP2023577349A 2021-06-16 2022-06-15 神経変性疾患の治療のための、カルボン酸基を含むアゼチジニル化合物 Pending JP2024522718A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163211313P 2021-06-16 2021-06-16
US63/211,313 2021-06-16
PCT/US2022/033523 WO2022266162A1 (en) 2021-06-16 2022-06-15 Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
JP2024522718A JP2024522718A (ja) 2024-06-21
JP2024522718A5 true JP2024522718A5 (enExample) 2025-06-23

Family

ID=82595041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577349A Pending JP2024522718A (ja) 2021-06-16 2022-06-15 神経変性疾患の治療のための、カルボン酸基を含むアゼチジニル化合物

Country Status (13)

Country Link
US (2) US11919879B2 (enExample)
EP (1) EP4355729A1 (enExample)
JP (1) JP2024522718A (enExample)
KR (1) KR20240021883A (enExample)
CN (1) CN117500785A (enExample)
AR (1) AR126159A1 (enExample)
AU (1) AU2022291768A1 (enExample)
BR (1) BR112023023420A2 (enExample)
CA (1) CA3217423A1 (enExample)
IL (1) IL308122A (enExample)
MX (1) MX2023014197A (enExample)
TW (1) TW202317534A (enExample)
WO (1) WO2022266162A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240021883A (ko) * 2021-06-16 2024-02-19 셀진 코포레이션 신경변성 질환의 치료를 위한 카르복실산 기를 포함하는 아제티디닐 화합물
US20260209203A1 (en) * 2022-12-16 2026-07-23 Celgene Corporation Heterocyclic Compounds as Modulators of S1P5
CN121399098A (zh) 2023-06-30 2026-01-23 赛诺菲 取代的环状化合物以及治疗苯丙酮尿症和其他氨基酸尿症的方法
WO2026008750A1 (en) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2026119962A1 (en) 2024-12-04 2026-06-11 Syngenta Crop Protection Ag Novel phenyl carboxamide compounds

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO167087C (no) 1985-10-25 1991-10-02 Secr Defence Brit Fremgangsmaate for fremstilling av en nitratester.
US5561227A (en) 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
DE69616366T2 (de) 1995-09-01 2002-07-04 Upjohn Co Phenyloxazolidinone mit einer c-c-bindung zu 4-8 gliedrigen heterocyclen
WO2000005214A2 (en) 1998-07-24 2000-02-03 Pfizer Inc. Isoquinolines as urokinase inhibitors
US6821998B2 (en) 2001-08-30 2004-11-23 Chemocentryx, Inc. Arylamines as inhibitors of chemokine binding to US28
AU2003249937A1 (en) 2002-07-12 2004-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
ATE496024T1 (de) 2002-12-20 2011-02-15 Merck Sharp & Dohme 1-(amino)indane als edg-rezeptoragonisten
CA2509406C (en) 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
WO2007109330A2 (en) * 2006-03-21 2007-09-27 Epix Delaware, Inc. S1p receptor modulating compounds
CA2668070A1 (en) 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
US20090137549A1 (en) 2006-11-09 2009-05-28 Paul John Edward Novel compounds useful for the treatment of degenerative & inflamatory diseases
WO2010056788A1 (en) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
WO2010092371A1 (en) 2009-02-10 2010-08-19 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
WO2011036889A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
GB201002563D0 (en) 2010-02-15 2010-03-31 Cambridge Entpr Ltd Compounds
CA2800578A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen-heterocyclic compounds as phosphodiesterase 10 inhibitors
CN103221404B (zh) * 2010-05-13 2015-12-16 安姆根有限公司 可用作pde10抑制剂的不饱和氮杂环化合物
WO2012082947A1 (en) 2010-12-16 2012-06-21 Irm Llc Compounds and compositions as tgr5 agonists
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CN104271568B (zh) 2012-05-09 2016-05-04 硕腾服务有限责任公司 作为抗寄生虫剂的氮杂环丁烷衍生物
AR092348A1 (es) 2012-07-11 2015-04-15 Hoffmann La Roche DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc
EA201590953A1 (ru) 2012-11-16 2015-08-31 Бристол-Майерс Сквибб Компани Пирролидиновые модуляторы gpr40
JP2016533375A (ja) 2013-10-17 2016-10-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノテトラリン誘導体およびアミノインダン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用
KR20160100407A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
FR3017867A1 (fr) * 2014-02-21 2015-08-28 Inventiva Nouveaux composes de type phenylazetidine carboxylate ou carboxamide
DK3140296T3 (en) 2014-05-07 2018-07-23 Bristol Myers Squibb Co PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES
WO2016040225A1 (en) 2014-09-09 2016-03-17 Bristol-Myers Squibb Company Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators
US11219625B2 (en) 2015-07-24 2022-01-11 Yale University Inhibitors of N-linked glycosylation and methods using same
FI3362445T3 (fi) 2015-10-12 2023-03-21 Chong Kun Dang Pharmaceutical Corp Oksadiatsoliamiinijohdannaisyhdisteitä histonideasetylaasi 6:n inhibiittoreina ja niitä käsittävä farmaseuttinen koostumus
WO2017131149A1 (ja) * 2016-01-29 2017-08-03 小野薬品工業株式会社 テトラヒドロナフタレン誘導体
PT3426243T (pt) 2016-03-09 2021-08-19 Raze Therapeutics Inc Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos
WO2017205425A1 (en) 2016-05-24 2017-11-30 President And Fellows Of Harvard College Compounds for organic light emitting diode materials
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
AR110988A1 (es) 2017-02-21 2019-05-22 Sanofi Sa Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados
JP7365332B2 (ja) 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Cdk8/19阻害薬としての新規ヘテロ環式化合物
WO2019141803A1 (en) 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
CN113039181B (zh) 2018-08-16 2024-08-13 勃林格殷格翰国际有限公司 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物
AU2019321588C1 (en) 2018-08-17 2026-05-14 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
WO2020071550A1 (ja) 2018-10-04 2020-04-09 京都薬品工業株式会社 Cdk8阻害剤およびその用途
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
CN111484479B (zh) 2019-01-25 2023-06-13 四川科伦博泰生物医药股份有限公司 氮杂环化合物、包含其的药物组合物及其制备方法和用途
CN114072405A (zh) 2019-07-03 2022-02-18 豪夫迈·罗氏有限公司 杂环单酰基甘油脂肪酶(magl)抑制剂
EP4019496B1 (en) * 2019-08-20 2024-06-05 ONO Pharmaceutical Co., Ltd. Salt and crystal form of compound having agonistic activity to s1p5 receptor
CN112887914A (zh) * 2019-11-30 2021-06-01 深圳市海思半导体有限公司 终端间定位方法及装置
CN111704613B (zh) 2020-06-23 2021-07-06 中国人民解放军军事科学院军事医学研究院 咪唑类衍生物及其作为trpv4抑制剂的用途
CN116685313A (zh) 2020-12-23 2023-09-01 细胞基因公司 用于治疗神经变性疾病的含有茚满基的羧酸化合物
KR20240021883A (ko) * 2021-06-16 2024-02-19 셀진 코포레이션 신경변성 질환의 치료를 위한 카르복실산 기를 포함하는 아제티디닐 화합물

Similar Documents

Publication Publication Date Title
JP2022185107A5 (enExample)
JP2019518766A5 (enExample)
JP2020502047A5 (enExample)
JP2010530881A5 (enExample)
JP2024512154A5 (enExample)
JP2018518537A5 (enExample)
JP2018505898A5 (enExample)
JP2012522759A5 (enExample)
JP2020527175A5 (enExample)
JP2020533352A5 (enExample)
JP2022533069A5 (enExample)
JP2019518050A5 (enExample)
JP2023535453A5 (enExample)
RU2010107169A (ru) Фармацевтическая композиция, содержащая оптически активное соединение, обладающее активностью агониста рецептора тромбопоэтина, и промежуточное соединение для этого
JP2023511349A5 (enExample)
JP2013542267A5 (enExample)
JP2021512913A5 (enExample)
JP2005539045A5 (enExample)
JP2020063289A5 (enExample)
JP2010522710A5 (enExample)
JP2003529602A5 (enExample)
JP2024546678A5 (enExample)
JP2025516719A5 (enExample)
JP2010535706A5 (enExample)
JP2013525490A5 (enExample)